Payment overview · 2025
General Payments
$239.52
8 reported records · 6 companies
Healthcare provider profile · identity verified
Addy Reine, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LA PLACE, LA · NPI 1881135176
Verified facts
What the public records show
CMS Open Payments records show Addy Reine, MD received $239.52 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 63.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.30 | 63.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.35 | 9.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.13 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.31 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.61 | 6.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.82 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.52 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $137.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $23.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 157 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
157 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
98 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
196 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 885 | 292 |
| Amlodipine Besylate | Amlodipine Besylate | 689 | 207 |
| Losartan Potassium | Losartan Potassium | 515 | 162 |
| Metoprolol Succinate | Metoprolol Succinate | 440 | 132 |
| Gabapentin | Gabapentin | 352 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 327 | 87 |
| Furosemide | Furosemide | 293 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 89 |
| Metformin Hcl | Metformin Hcl | 278 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 265 | 83 |
| Omeprazole | Omeprazole | 233 | 73 |
| Alendronate Sodium | Alendronate Sodium | 214 | 63 |
| Trazodone Hcl | Trazodone Hcl | 211 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 68 |
| Ozempic | Semaglutide | 196 | 35 |
| Lisinopril | Lisinopril | 195 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 57 |
| Alprazolam | Alprazolam | 189 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 58 |
| Mounjaro | Tirzepatide | 157 | 22 |
| Meloxicam | Meloxicam | 147 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 44 |
| Allopurinol | Allopurinol | 143 | 47 |
| Eliquis | Apixaban | 133 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 43 |
| Carvedilol | Carvedilol | 128 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 41 |
| Glimepiride | Glimepiride | 127 | 35 |
| Potassium Chloride | Potassium Chloride | 120 | 37 |
| Ezetimibe | Ezetimibe | 119 | 39 |
| Tramadol Hcl | Tramadol Hcl | 117 | 47 |
| Jardiance | Empagliflozin | 113 | 32 |
| Glipizide Er | Glipizide | 112 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 39 |
| Simvastatin | Simvastatin | 108 | 32 |
| Mirtazapine | Mirtazapine | 107 | 29 |
| Finasteride | Finasteride | 102 | 30 |
| Sertraline Hcl | Sertraline Hcl | 102 | 38 |
| Montelukast Sodium | Montelukast Sodium | 99 | 34 |
| Trulicity | Dulaglutide | 98 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 88 | 24 |
| Metformin Hcl Er | Metformin Hcl | 85 | 33 |
| Spironolactone | Spironolactone | 81 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 26 |
| Valsartan | Valsartan | 78 | 19 |
| Nifedipine Er | Nifedipine | 77 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 18 |
| Linzess | Linaclotide | 71 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 22 |
| Methocarbamol | Methocarbamol | 68 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 21 |
| Meclizine Hcl | Meclizine Hcl | 62 | 29 |
| Bupropion Xl | Bupropion Hcl | 59 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 54 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 20 |
| Xarelto | Rivaroxaban | 54 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 18 |
| Atenolol | Atenolol | 50 | 15 |
| Irbesartan | Irbesartan | 49 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 14 |
| Cefdinir | Cefdinir | 48 | 35 |
| Memantine Hcl | Memantine Hcl | 47 | 14 |
| Lorazepam | Lorazepam | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Levofloxacin | Levofloxacin | 40 | 33 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | 12 |
| Buspirone Hcl | Buspirone Hcl | 38 | 12 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Prednisone | Prednisone | 38 | 17 |
| Temazepam | Temazepam | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 14 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Estradiol | Estradiol | 35 | 18 |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 11 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 22 |
| Topiramate | Topiramate | 33 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 23 |
| Levemir Flexpen | Insulin Detemir | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | 14 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 29 | 18 |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 22 |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 11 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Valacyclovir | Valacyclovir Hcl | 19 | 13 |
| Cilostazol | Cilostazol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 13 |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $239.52 · 8 records | Novo Nordisk Inc | Dexcom G6 Transmitter, FREESTYLE LIBRE, MOUNJARO, PREVNAR 20, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error